We understand that it can be challenging to gain clarity and perspective on breaking Parkinson's news. Q&As in this section are conducted with leading experts in the Parkinson's disease research field to quickly provide an informed, impartial opinion on new findings -- and to get to the bottom of what they might mean for researchers and people living with PD today.
News in Context: Canadian Mennonite Family Stands Up For Parkinson's Research Helping to Link New Gene to PD
July 26, 2012
Recently, a team of geneticists led by Michael J. Fox Foundation (MJFF) Scientific Advisory Board member Matt Farrer, PhD, found the latest gene to be implicated in late--onset forms of Parkinson's disease (PD).
Farrer's team, from the University of British Columbia, Vancouver Coastal Health and including University of Saskatchewan neurologists Drs. Alex and Ali Rajput, made the discovery thanks largely to the long--standing and generous investment of a Canadian Mennonite family of Dutch--Germ...Read More
News in Context: Isradipine Deemed Safe For People With Parkinson's, But Will it Work as Disease-Modifying Drug?
July 25, 2012
At last month's Movement Disorder Society's Annual Congress, a clinical study of isradipine (brand name Dynacirc CR), a drug currently approved to treat high blood pressure, was awarded Blue Ribbon status for work investigating the drug's potential as a disease-modifying therapy for Parkinson's disease (PD). The study, called STEADY-PD (Safety, Tolerability, and Efficacy Assessment of Dynacirc CR for PD), was funded by The Michael J. Fox Foundation (MJFF), and led by principal investigator Tanya...Read More
May 01, 2012
Researchers funded by The Michael J. Fox Foundation (MJFF) have identified the best clinical scale for measuring patient response to therapies to treat dyskinesia, the debilitating, uncontrollable movements that are often a side effect of Parkinson's disease (PD) drugs.
The $1-million study, led by co-coordinating principal investigators Chris Goetz, MD, and Glenn Stebbins, PhD, of Rush University Medical Center, was launched in 2010 at eight sites across the United States, Canada and Europe. I...Read More
April 11, 2012
Study of Antidepressants in Parkinson's disease or SAD-PD, a first-of-its-kind study published today in the medical journal Neurology, has found that two common antidepressants ease depression in people with Parkinson's disease (PD) without aggravating motor symptoms. The drugs tested in the study, led by Michael J. Fox Foundation (MJFF) Scientific Advisory Board member Irene Hegeman Richard, MD, of the University of Rochester, were paroxetine (brand name Paxil) and venlafaxine extended release ...Read More
March 21, 2012
On Wednesday, March 21, biotech company Addex Therapeutics announced positive results from a Phase IIa clinical study of their drug candidate dipraglurant to treat dyskinesia in people with Parkinson's disease (PD).
Dipraglurant complements levodopa (long the gold standard for treating PD) by targeting the brain's glutamate system. The drug would allow patients taking levodopa to experience better "on" times without dyskinesia that so often affect those on a levodopa regimen.
MJFF spoke with B...Read More